2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-157958
    α7 nAChR Modulator-3
    α7 nAChR modulator-3 (Compound 6p) is a α7 nAChR positive allosteric Modulator with a IC50 value of 1.3 μM. α7 nAChR Modulator-3 can be used to inhibit auditory gating defects in a mouse schizophrenic model.
    α7 nAChR Modulator-3
  • HY-157978
    AChE-IN-59 2957916-86-6
    AChE-IN-59 (compounds 3b) is an AChE inhibitor, with an IC50 value of 0.05 μM. AChE-IN-59 can inhibit the aggregation of Aβ1-42, protect nerve cells and penetrate the blood-brain barrier well. AChE-IN-59 can be used for the research of Alzheimer's disease (AD).
    AChE-IN-59
  • HY-157981
    AChE-IN-60
    AChE-IN-60 (compound 6k) is a potant acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitor with IC50s of 27 nM and 43 nM, respectively. AChE-IN-60 also inhibits monoamine oxidase (MAO)-A and MAO-B with IC50s of 353 nM and 716 nM, respectively.
    AChE-IN-60
  • HY-157982
    BChE-IN-28
    BChE-IN-28 (compound 6J) is a selective butyrylcholinesterase (BChE) inhibitor with an IC50 of 8 nM and a Ki of 12.16 nM. BChE-IN-28 shows the lower inhibition against AChE, MAO-A and MAO-B.
    BChE-IN-28
  • HY-157992
    LM-021 1022282-98-9
    LM-021 is a coumarin-chalcone derivative with anti-aggregatory, antioxidant, neuroprotective and anti-inflammatory properties which suppresses nitric oxide (NO), IL-1β, IL-6, TNF-α production, CD68 antigen (CD68) and histocompatibility-2 (MHCII) expression. LM-021 also attenuates the increase of caspase 1 activity, lactate dehydrogenase release and ROS level. LM-021 can be used for neurological research.
    LM-021
  • HY-157996
    CSF1R-IN-21 2935479-62-0
    CSF1R-IN-21 (compound 7e) is a CSF-1R Inhibitor with an IC50 value of 31 nM. CSF1R-IN-21 inhibits CSF-1R auto-phosphorylation and can be used for the research of neurodegenerative diseases .
    CSF1R-IN-21
  • HY-158013
    JJC8-088 1627576-82-2
    JJC8-088 is a potent inhibitor of DAT. JJC8-088 is a novel Modafinil-derived ligands. JJC8-088 can be used to study psychostimulant use disorders.
    JJC8-088
  • HY-158014
    JJC8-089 1627576-64-0
    JJC8-089 is a dopamine transporter (DAT) inhibitor that may improve motivational dysfunction and increase effortful behavior in goal-directed activities. JJC8-089 significantly reversed the low-effort effects induced by the VMAT-2 inhibitor Tetrabenazine (HY-B0590) in rats and increased the choice of high-effort fixed-ratio 5-bar presses versus food intake. .
    JJC8-089
  • HY-158030
    HDAC6-IN-37 2986486-82-0
    HDAC6-IN-37 (compound W5) is an inhibitor of HDAC6 and has neuroprotective effects. HDAC6-IN-37 can restore the morphology of hippocampal neurons, reduce the expression of Aβ, Tau, and p-Tau proteins in the hippocampus of AD rats, and inhibit the formation of senile plaques and neurofibrillary tangles. Thus, HDAC6-IN-37 improves the Aβ/Cu2+-induced AD model in rats, regulates oxidative stress status, and balances neurotransmitter disorders in brain tissue.
    HDAC6-IN-37
  • HY-158051
    CIDD-0072424 1620195-03-0
    CIDD-0072424 selectively inhibits Protein Kinase C-epsilon (PKCε) (Ki=54 nM). CIDD-0072424 reduces ethanol consumption and preference in a dose-dependent manner.
    CIDD-0072424
  • HY-158092
    ChEs/MAOs-IN-2 693268-77-8
    ChEs/MAOs-IN-2 (compound a11) is a cholinesterases and monoamine oxidases inhibitor with IC50 values of 0.10, 0.20, 0.30, 0.40 µM for MAO-A, MAO-B, AChE, and BChE, respectively. ChEs/MAOs-IN-2 has the potential for the research of Alzheimer's disease.
    ChEs/MAOs-IN-2
  • HY-158130
    FKBP51-Hsp90-IN-1 433313-64-5
    FKBP51-Hsp90-IN-1 (Compound D10) is a selective inhibitor of the FKBP51-Hsp90 protein-protein interaction, with an IC50 value of 0.1 μM against FKBP51. FKBP51-Hsp90-IN-1 can be used in the research of stress-related diseases, Alzheimer's disease, and metabolic disorders.
    FKBP51-Hsp90-IN-1
  • HY-158131
    FKBP51-Hsp90-IN-2 601511-07-3
    FKBP51-Hsp90-IN-2 (Compound E08) is a selective FKBP51-Hsp90 protein-protein interaction inhibitor with IC50 values of 0.4 µM and 5 µM for FKBP51 and FKBP52, respectively. FKBP51-Hsp90-IN-2 also effectively stimulates cellular energy metabolism and neurite growth. FKBP51-Hsp90-IN-2 can be used in research on neurodegenerative diseases and cancer.
    FKBP51-Hsp90-IN-2
  • HY-158148
    CSF1R-IN-23 2935480-17-2
    CSF1R-IN-23 (Compound 7dri) is a selective inhibitor for colony-stimulating factor-1 receptor (CSF1R), with IC50 of 36.1 nM. CSF1R-IN-23 serves as antineuroinflammatory agent in mouse model. CSF1R-IN-23 is blood brain barrier (BBB) permeable.
    CSF1R-IN-23
  • HY-158179
    A3AR agonist 3 3032474-53-3
    A3AR agonist 3 (Compound 15A) is a A3 adenosine receptor (A3AR) agonist, with Ki and EC50 values of 2.27 and 0.20 nM for hA3 and cAMP, respectivelly. A3AR agonist 3 can be used for the research of neuroinflammation.
    A3AR agonist 3
  • HY-158198
    PRXS571 2396759-31-0
    PRXS571 is a potent modulator of the neuronal integrated stress response (ISR) and can be used in neural-related research.
    PRXS571
  • HY-158212
    Dyrk1A-IN-8 101578-13-6
    Dyrk1A-IN-8 (compound 4C) is a potent inhibitor of Dyrk1A , with the IC50 of 209 nM. Dyrk1A-IN-8 plays an important role in neurodegenerative diseases.
    Dyrk1A-IN-8
  • HY-158236
    ORL1 antagonist 2 1169982-72-2
    ORL1 antagonist 2 (1B) is an opioid receptor-Like 1 (ORL1) antagonist, usd in P-glycoprotein (P-gp) research.
    ORL1 antagonist 2
  • HY-158237
    PDE10A-IN-3 1006889-85-5
    PDE10A-IN-3 (Compound 8a) is an inhibitor of phosphodiesterase 10A (PDE10A). PDE10A-IN-3 can be used in schizophrenia research.
    PDE10A-IN-3
  • HY-158261
    AChE-IN-63 876685-78-8
    AChE-IN-63 (Compound 5AD) is a selective inhibitor of hAChE (IC50=0.103 μM). AChE-IN-63 also inhibits hBChE and hBACE-1 (IC50= 10 μM (hBChE); 1.342 μM (hBACE-1)). AChE-IN-63 inhibits Aβ aggregation, preventing the formation and deposition of Aβ1-42. AChE-IN-63 can effectively penetrate the blood-brain barrier and is orally effective. It is primarily used in Alzheimer's disease research.
    AChE-IN-63
Cat. No. Product Name / Synonyms Application Reactivity